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Abstract
Invasive fungal infections can be devastating, particularly in immunocompromised patients, and
difficult to treat with systemic drugs. Furthermore, systemic administration of those medications can
have severe side effects. We have developed an injectable local antifungal treatment for direct
administration into existing or potential sites of fungal infection. Amphotericin B (AmB), a
hydrophobic, potent, and broad-spectrum antifungal agent, was rendered water-soluble by
conjugation to a dextran-aldehyde polymer. The dextran-aldehyde-AmB conjugate retained
antifungal efficacy against C. albicans. Mixing carboxymethylcellulose-hydrazide with dextran-
aldehyde formed a gel that cross-linked in situ by formation of hydrazone bonds. The gel provided
in vitro release of antifungal activity for 11 days, and contact with the gel killed Candida for three
weeks. There was no apparent tissue toxicity in the murine peritoneum and the gel caused no
adhesions. Gels produced by entrapment of a suspension of AmB in CMC-dextran without
conjugation of drug to polymers did not release fungicidal activity, but did kill on contact. Injectable
systems of these types, containing soluble or insoluble drug formulations, could be useful for
treatment of local antifungal infections, with or without concurrent systemic therapy.
Introduction
Fungal infections are a serious threat to many patient populations, particularly the immuno-
compromised [1]. Treatment of localized fungal infections, such as osteoarticular infections,
can be particularily refractory, perhaps because they take on an abcess-like or granulomatous
form where they are relatively sequestered from circulating drugs. Infection of medical devices
can necessitate their removal. Furthermore, systemically delivered antifungal drugs can have
severe and potentially lethal side effects.
Controlled release systems can address both issues. Consequently, there has been increasing
interest, in both research and clinical practice, in providing localized treatments of infectious
processes, e.g. delivery of gentamicin using various materials as delivery systems [2,3].
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Specifically antifungal devices have included antifungal hydrogels for prophylaxis [4] and a
range of topical creams for epidermal [5], buccal [6], or vaginal application [7], and medical
cements containing antifungal drugs [8]. By providing a drug depot at the site of infection,
such devices have the potential to achieve very high local drug concentrations without
significant systemic distribution [9].
Treatment of localized infections within the body without having to resort to surgery requires
that the drug delivery system be injectable. However, since control of drug release is closely
related to drug viscosity, formulations that are easy to inject often control drug release poorly
[9]. In order to allow the creation of a high-viscosity matrix while maintaining ease of injection,
we have used a hydrogel composed of dextran and cellulose that cross-links in situ, forming
hydrazone bonds [10]. This approach maintains the hydrogel at the site of injection. Tissue
reaction to cellulose-dextran gels has been previously shown to be benign and to prevent
adhesions when injected into the peritoneum of rabbits, and the crosslinking chemistry of
hydrazone bond formation in vivo does not have any adverse tissue effects [11,12]. Here, to
control the release of the antifungal from the hydrogel, we conjugated a potent antifungal agent,
amphotericin B (AmB) to that in situ cross-linking hydrogel (Scheme 1), and determined its
antifungal activity and intraperitoneal biocompatibility
Materials and Methods
Materials
Dextran (100–200 kDa), carboxymethylcellulose (250 kDa, medium viscosity), sodium
periodate, polyethylene glycol, sodium hydroxide, hydroxylamine, adipic dihydrazide, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), 1-hydroxybenzotriazole (HOBt),
amphotericin B (AmB), glucose, histidine and leucine were obtained from Sigma Aldrich (St.
Louis, MO, USA). Phosphate buffered saline (pH 7.4) was obtained from Invitrogen. Yeast
nitrogen base (YNB) and yeast extract peptone (YEP) media from Difco (Beckton, Dickinson
and Company, Franklin Lakes, NJ, USA) were used.
Oxidation of dextran (to dextran-aldehyde; dextran-CHO)
The oxidation was conducted as reported [13]. Dextran (3 g) was dissolved in 300 ml of
deionized water and sodium periodate (1.604 g) suspended in 10 ml of deionized water was
added dropwise with vigourous stirring – the reaction mixture was stirred for a further 2 hours.
Polyethylene glycol (800 μl) was added to stop the reaction and the reaction mixture was stirred
for an additional hour. The solution was dialysed against deionized water in dialysis membranes
of 3,500 MWCO, followed by lyophilization. The extent of oxidation was calculated by stirring
0.1 g of oxidized polymer in a 0.25 M solution of hydroxylamine hydrochloride (25 ml) for 3
hours and then titrating against 0.1 M sodium hydroxide [13]. The extent of oxidation was
controlled by the amount of sodium periodate added to the reaction mixture, Table 1. The
oxidized dextran is called dextran-CHOn where n refers to the number of aldehyde groups per
100 units of glucose (dextran subunits) units.
Functionalization of carboxymethylcellulose (to CMC-hydrazide; CMC-ADH)
The functionalization of carboxymethylcellulose with hydrazine groups was carried out using
the method published by Bulpitt et al [10]. Carboxymethylcellulose (1 g, medium viscosity)
was dissolved in 200 ml of deionized water. Adipic dihydrazide (3 g) was added and the pH
was measured to be at 7.4. HOBt (258 mg suspended in 2 ml of a dimethylsulfoxide:water
(1:1) mixture) was then added followed by EDC (262 mg in 2 ml of a dimethylsulfoxide:water
(1:1) mixture). The pH was adjusted to 6.8 and kept there by adding small amounts of 0.1 M
sodium hydroxide when necessary while stirring for 6–7 hours. The solution was dialysed
against deionized water using 10,000 MWCO membranes, followed by lyophilization. The
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degree of functionalization was then deduced by the nitrogen content using CHN elemental
analysis of the polymer and 1H NMR analysis. Elemental analysis is described below.
For 1H-NMR analysis, the polymer was dissolved in D2O and the analysis was conducted on
a Varian Unity 300 spectrophotometer.
Conjugation of AmB to dextran-CHO (dextran-aldehyde)
The conjugation was conducted by a modification of the method of Falk et al [14]: Dextran-
CHO (750 mg) and AmB were dissolved in 0.2 M sodium tetraborate buffer (10 ml) adjusted
to pH 11 with 2 M NaOH and stirred at 37°C for 2 hours in the dark. The solution was then
dialysed using membranes (3500 MWCO) at 4°C in 5 l of deionized water in the dark with a
minimum of 8 water changes with 4 hours between each water change. The solution was then
centrifuged at 2,000 rpm for 10 minutes to ensure removal of any precipitated AmB and the
solution was freeze dried and stored at 4°C in the dark before use. The nomenclature dextran-
CHOn-AmBm was used where n refers to the number of aldehyde groups per 100 glucose units
(%) of the oxidized dextran used and m referes to the loading of AmB (in mg/g) on the dextran-
CHO. The n values used are the experimental oxidation values while the m values are the
theoretical values for the amount of amphotericin B conjugated to the polymer. The UV
absorption spectra, minimum inhibitory concentrations against C. albicans and extinction
coefficients of dextran-CHOn-AmBm with varying m and n were examined and compared.
Molecular Weight Measurements
The molecular weight of CMC-ADH, dextran-CHO33, dextran-CHO66 and dextran-CHO75
were deduced by size exclusion chromatography (SEC) using the Waters Alliance 2695
Analytical HPLC coupled with a Waters 2410 Refractive Index Detector (LIMS 899) and a
PL Aquagel-OH Mixed 8μm column (Intertek ASG, Manchester, UK). These samples were
run with 0.1 M sodium nitrate eluent at a rate of 1 ml/min for a run time of 30 minutes. The
molecular weights of dextran-CHO33-AmB62.5, Dextran-CHO66-AmB 62.5 and Dextran-
CHO75-AmB62.5 were measured on the same system using a TSK Gel G2000 SWxl column
and were run with with 0.1 M sodium nitrate eluent at a rate of 0.5 ml/min for a run time of 30
minutes. The molecular weights were calculated based on pullulan standards. SEC was carried
out by Intertek ASG, Manchester, UK.
Elemental Analysis
Elemental analysis (CHN) of the CMC-ADH, dextran-CHOn and dextran-CHOn-AmBm
polymer-drug conjugates was conducted by completely burning the polymer/polymer-drug
conjugate at 1800 °C, and measuring the concentrations of CO2, N2, and H2O with a CHN
analyzer (PE-2400II; Perkin-Elmer, Waltham, MA, USA). The weight percentage of C, H, and
N was determined based on the measured gas composition.
Formation of blank and AmB loaded CMC-Dextran gels
Dextran-CHO50 (60 mg) was dissolved in 1 ml of PBS over a few hours. CMC-ADH (25 mg)
was dissolved in 1 ml of PBS overnight. Each polymer was loaded separately into a 1 ml syringe
and placed in a double barrel injector with one needle (21 guage) at the tip. The gels were
injected into a 6 mm diameter and 3 mm high rubber mold between two glass slides and allowed
to set for 30 minutes at 37 °C. Gelation occurs in 2–3 seconds. When adding AmB, the AmB
formulation was suspended (insoluble form) or dissolved (souble dextran-CHOn-AmBm
formulation) in the dextran-CHO50 solution before loading into the syringe. For the insoluble
AmB, 3 mg of drug was suspended in 1 ml of dextran-CHO50 solution. For the soluble dextran-
CHOn-AmBm, an equivalent amount of AmB was added, e.g. 48 mg of dextran-CHO33-
AmB62.5 was dissolved in the dextran-CHO50 solution.
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Characterization of CMC-Dextran gels
Scanning electron microscopy was conducted using a FEI/Philips XL30 FEG ESEM (Oregon,
USA). Samples were lyophilized before SEM analysis. SEM images were analyzed using
Gatan Digital Micrograph Version 3.6.5 (Warrendale, PA, USA). Mechanical strength
compression testing was conducted using an Instron (Model 1011, High Wycombe, UK) with
a 100 N load cell. The swelling rate and rate of degradation of the CMC-Dextran gels was
assessed by incubating each gel (6 mm × 3 mm cylindrical disc) in PBS (1 ml) and shaking at
37°C in the dark. The gel disc was weighed and placed into fresh PBS every 24 hours. Gel
discs were also lyophilized and their swelling ratio from dry mass to wet mass in PBS with
shaking at 37°C in 24 hours was determined.
In vitro release kinetics from CMC-Dextran gels
Gel discs containing AmB (1.5 mg/ml), dextran-CHO33-AmB62.5 (24 mg/ml), dextran-
CHO66-AmB62.5 (24 mg/ml) and dextran-CHO75-AmB62.5 (24 mg/ml) were prepared and
placed in 1 ml of PBS in a 24 well plate. The gels were shaken at 150 rpm in an incubator at
37°C in the dark and were placed in a new well containing fresh PBS every 24 hours. The PBS
was then analysed by UV-visible spectroscopy for dextran-CHOn-AmBm content.
Antifungal activity assay [4]
Growth of C. albicans strain SC5314 was regrown from frozen stocks from the Whitehead
Institute. In all cases, C. albicans was maintained on YEP–agar plates. For experiments, YEP
(2x, 50 ml) was inoculated with one colony of Candida overnight. After that time, the
suspension was centrifuged (5 min at 8000 g), the supernatant was discarded, and the cells
were washed twice with PBS 7.2 (50 ml). The cells were counted on a hemocytometer and
diluted to 0.5–1 × 107 or 2–4 × 107 cells/ml in YNB medium with 50 mM glucose. The actual
measure of fungal survival was a colony growth assay. The details of these experiments follow.
Drug Potency—To quantify the minimum inhibitory concentration (MIC) of each AmB drug
formulation, 225 μl of drug solution was added to 75 μl of fresh YNB containing 2–4 × 107
C. albicans SC5314 cells/ml. After 2 h the suspension was diluted to a concentration of 1:1,000,
200 μl were plated onto YEP agar plates, and incubated at 37°C for 24 h, after which viable
colonies were counted. Control samples were prepared by adding 225 μl of YNB to 75 μl of
YNB containing 2–4 × 107 cells/ml C. albicans SC5314. The drug solutions/suspensions were
tested at different concentrations and at different time points after shaking (150 rpm) at 37°C
in the dark. Before testing each solution/suspension was centrifuged ((5 min at 8000 g).
Halo Test—200 μl of fresh YNB containing 0.5–1 × 107 cells/ml C. albicans SC5314 were
plated onto a YEP-agar plate. The gel disc (6 mm × 3 mm, 150 mg) being tested was placed
onto the centre of the plate and incubated for 24 hours at 37°C in the dark before being examined
for a “halo” or “zone of inhibition” surrounding the gel disc.
Fungicidal effect of direct exposure to the gels—The gels (6 mm × 3 mm, 150 mg)
were placed in the wells of a 24-well tissue culture plate with 1ml of the Candida suspension
(0.5–1 × 107 cells in YNB). The disks were incubated for 2 h, at 37°C while shaking at 100
rpm. Then the disks were removed, and the remaining medium was vigorously stirred and then
diluted to a concentration of 1:1,000. Next, 200 μl of the diluted medium were plated on YEP
agar plates. The YEP plates were incubated at 37°C for 24 h, and colonies were counted.
Fungicidal effect of drug release—To assess the fungicidal effect of the AmB
formulation released from the gel, hydrogels were immersed in 1 ml of YNB medium with 50
mM glucose and incubated at 37°C at 100 rpm. The incubation medium was removed
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completely, and the gel was immersed in fresh medium daily. To 225 μl of YNB medium
collected at each time point, we added 75 μl of fresh YNB containing 2–4 × 107 C. albicans
SC5314 cells/ml. After 2 h the suspension was diluted to a concentration of 1:1,000, 200 μl
were plated onto YEP agar plates, and incubated at 37°C for 24 h, after which viable colonies
were counted. Control samples were prepared by adding 75 μl of YNB containing 2–4 × 107
cells/ml C. albicans SC5314 to 225 μl of YNB.
The lower detectable limit of candidal survival due to the dilution steps in the assays described
above was 0.2 %.
Hemolysis assay
0.2 ml of AmB and dextran-CHOn-AmBm suspensions or solutions at concentrations ranging
from 5 μg to 1 mg/ml were incubated in human whole blood with shaking for 1 hr. The samples
were then centrifuged at 3000 rpm for 20 minutes and the concentration of hemoglobin
(absorbance at 545 nm) in the supernatant was determined by UV absorption spectroscopy. A
negative control of PBS and positive control of deionized water were used.
In vivo studies
All the animals were cared for in compliance with protocols approved by the Animal Care and
Use Committee at the Massachusetts Institiute of Technology, and the Principles of Laboratory
Animal Care (NIH publication #85-23, revised 1985). SV129 mice weighing 25 g were
purchased from Charles River Labs (Wilmington, MA) and housed in groups in a 6 AM – 6
PM light dark cycle. CMC-ADH and dextran-CHO were sterilized by UV irradiation for 2 h
and then dissolved in sterile phosphate buffered saline (CMC-ADH 2.5 % w/v, dextran-
CHO50 6% w/v). Anaesthesia was induced briefly, prior to injection, with isofluroane in 100%
oxygen. Each mouse received one intraperitoneal injection, from a double barrel syringe, of 1
ml of hydrogel. The three experimental groups were (a) CMC-ADH (12.5 mg), dextran-
CHO50 (30 mg), (b) CMC-ADH (12.5 mg), dextran-CHO50 (30 mg), dextran-CHO33-
AmB62.5 (0.96 mg) and (c) CMC-ADH (12.5 mg), dextran-CHO50 (30 mg), dextran-CHO66-
AmB62.5 (0.96 mg). There were three mice in each group. One mouse from each group was
sacrificed 7, 11 and 33 days after injection. Tissues recovered from the necropsy were fixed
in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for
histological examination using standard techniques.
Results
A formulation of amphotericin B (AmB) for treating localized infections in an injectable gel
form was achieved by combining two techniques: the solubilization of AmB by the conjugation
of the drug to dextran [15] and incorporation into an injectable crosslinking gel. Modifications
of the dextran are described as dextran-CHOn-AmBm, where n refers to the number of aldehyde
groups per 100 units of glucose (dextran subunits) units and m is the milligrams of AmB per
gram of dextran-CHO. CMC-dextran refers to crosslinked gels formed by mixing
carboxymethylcellulose-hydrazide (CMC-ADH) and dextran-aldehyde (dextran-CHO50).
Characterization of uncrosslinked AmB formulations
Amphotericin B—In methanolic solution, spectroscopy of AmB showed well resolved peaks
at 365, 387 and 406 nm (Fig. 1). An aqueous suspension of AmB exhibited a poorly resolved
spectrum (Fig. 1), due to its insolubility. The particle size of the aqueous AmB suspension was
~ 1000 ± 100 nm, in PBS and dextran-CHO50 (6% in PBS).
Oxidized dextrans—Dextran was modified such that there were 33–75 % of aldehyde
groups present on the polymer (Table 1). Dextran-CHOn did not show any absorption over the
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wavelength range of 300–500 nm, the range at which peaks were seen in the methanolic
solution of AmB and the aqueous solutions of dextran-CHOn-AmBm. The molecular weight
of the dextran was reduced significantly by oxidation with sodium periodate and the more
highly oxidized polymers had the lowest molecular weights, e.g. dextran-CHO33 and dextran-
CHO75 had molecular weights of 28 and 18 kDa respectively (Table 1). The degree of oxidation
of dextran, measured by reaction with hydroxylamine hydrochloride, was much lower than
that predicted from the mole percentage of periodate added, Table 1. This may be due to the
due to the formation of a stable six-membered hemiacetal which protects the aldehydes from
further reaction [13].
Conjugates of AmB to dextran—The free amine group of AmB reacted with the aldehyde
groups of the oxidized dextrans, forming an imine group [14]. When 50 mg of AmB was
conjugated to 750 mg of dextran-CHO33, no AmB precipitated during dialysis or centrifugation
before lyophilization, suggesting complete conjugation to the dextran-CHO33 (i.e. 62.5 mg
AmB per gram of dextran-CHO33). Elemental analysis showed that nitrogen was 0.11 ± 0.03
% of the mass, which was close to what would be expected stoichiometrically (0.09%) if AmB
were incorporated in proportion to the quantities of reagents added. Up to 100 mg of AmB
could be loaded on to 750 mg of dextran-CHO33 without precipitation; higher loadings were
not attempted. The amount of free aldehyde groups remaining on the oxidized dextrans after
reaction to AmB (Table 1), measured by reaction with hydroxylamine, was lower than expected
from the number of moles of AmB added. Possibly AmB, a relatively large molecule, masked
free aldehyde groups from hydroxylamine, giving a falsely low measurement. After the
conjugation reaction, the weight average molecular weight of the the dextran-CHO polymers
decreased from 18–28 kDa to 8.0 kDa (Table 1). One possible explanation for this is that the
physicochemical properties (e.g. intrinsic viscosity and hydrophobicity) of the dextran-CHO
polymer may have been altered by the conjugated amphotericin B moieties, which may have
lengthened the elution time of the dextran-CHOn-AmBm polymer drug conjugates from the
column, resulting in lower calculated molecular weights.
After conjugation of AmB to dextran-CHO, peaks were seen at wavelengths very similar to
those seen with AmB dissolved in methanol (362, 385 and 410 nm), but the intensity ratio of
the peaks was inverted (Fig. 1). Nishi et al reported that the UV-visible spectra of polyenes are
very sensitive to conformational changes induced by different molecular interactions, including
aggregation [16]. Thus the dextran polymer can influence the UV-visible spectra of the dextran-
CHOn-AmBm formulations (Fig. 1) and the UV-visible spectral changes observed after
conjugation of AmB to dextran-CHO may not be solely attributable to aggregation effects.
When the degree of oxidization of the dextran polymer was increased to 66% and the AmB
loading kept the same, the UV-visible absorption spectra and MICs remained the same as for
dextran-CHO33-AmB62.5, (Fig. S1–S2), although the number of free aldehyde groups present
on the dextran-CHO-AmB62.5, measured by hydroxylamine, increased from 6% to 15% (Table
1). Higher amounts of free aldehyde groups will allow for greater crosslinking of the dextran-
CHO-AmB to CMC-ADH when incorporated into the CMC-dextran gels. Similarly the
extinction coefficient of dextran-CHOn-AmB62.5 at 362 nm (10.5 ± 1.1 mg of dextran-CHOn-
AmBm/ml cm−1) was independent of the degree of oxidation (Fig. S3). This extinction
coefficient was used to determine the amount of dextran-CHOn-AmBm released over time in
vitro from the CMC-dextran gels. Thus, varying the degree of oxidation of the dextran polymer
used to solubilise the AmB did not alter the structure (as observed by UV-visible spectroscopy)
or antifungal activity of the final drug-polymer conjugate.
AmB could bind nonspecifically to unmodified dextran, in that the polymer turned yellow
when mixed with AmB solution, and the polymer then acquired antifungal activity. However,
AmB precipitated during dialysis when as little as 10 mg were combined with 750 mg of
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dextran, and the antifungal activity was much lower per unit of total mass than when conjugated
to dextran-CHO33-AmB12.5.
Antifungal activity—The antifungal potencies of a suspension of AmB, dextran-CHO33-
AmB12.5 and dextran-CHO33-AmB62.5 were compared (Fig. 2). Dextran-CHO33-AmB62.5 was
more potent than the suspension of AmB, with a minimum inhibitory concentration (MIC) of
3 μg/ml of AmB (0.048 mg/ml of dextran-CHO33-AmB62.5 conjugate) while the AmB
suspension did not kill below 10 μg/ml (Fig. 2). Dextran-CHO33-AmB12.5 and dextran-
CHO33-AmB62.5 were roughly equipotent in antifungal activity for a given concentration of
AmB present. Consequently, dextran-CHO33-AmB62.5, was five times more potent per unit
mass than dextran-CHO33-AmB12.5.
To assess the stability of antifungal activity, a solution of dextran-CHO33-AmB62.5 and a
suspension of AmB were incubated in darkness at 37°C with continuous mechanical agitation,
and aliquots of these compounds were added to a fungal culture at predetermined time points.
At a concentration of 0.1 mg/ml, AmB retained its fungicidal properties for 40 days in YNB
media, while 1.6 mg of dextran-CHO33-AmB62.5 per ml of YNB began to lose its antifungal
activity by day 28, (Fig. 3).
Hemocompatibility—It has been reported that hemolysis occurs with monomeric but not
aggregated forms of AmB [17]. None of our formulations - the AmB suspension or the dextran-
CHOm-AmBn conjugates - were hemolytic at concentrations of 5 – 1000 μg/ml of AmB. The
size of the aggregates in the AmB suspension was ~1 μm and resembled the poly-aggregate
form described by Espada et al in that hemolysis did not occur [17].
CMC-Dextran in situ crosslinking gels
CMC-ADH was synthesized as in Methods. Elemental analysis of the carbon, hydrogen and
nitrogen content of CMC-ADH indicated a degree of substitution of 51 % and NMR analysis
showed the presence of the methylene groups of adipic dihydrazide (1H NMR 1.6 ppm (s) and
2.3 ppm (d)). Gel discs (Fig. 4) were made by mixing CMC-ADH (2.5% w/v) with dextran-
CHO50 (6% w/v) leading to hydrazone bond formation [10] and gelation within seconds (see
Methods). Dextran-CHO50 was selected for formation of all cross-linked gels below – dextran-
CHO with 33 %, 66 % and 75 % aldehyde groups also formed good gel constructs, and could
have been used as well. The viscosity of higher concentrations of CMC-ADH prevented good
mixing with dextran-CHO50. Higher concentrations of dextran-CHO50 did not add to the
strength of the gel formed as assessed by mechanical strength compression tests (data not
shown) and thus were not deemed necessary. Gel discs (6 mm × 3 mm) retained their shape
(Fig. 4a) for 3 weeks when suspended in PBS or media, and could withstand pressures of up
to 4 N before breaking under a compressive strain. Hydrated gels swelled slowly to about 150
% of their original mass over 3 weeks. Lyophilized discs (Fig. 4b) swelled to 20 times their
dry mass in PBS at 37°C, to 150 mg in 24 hours.
CMC-dextran-AmB gels; Formation and in vitro release studies
AmB dextran conjugate-containing gels were formed by combining CMC-ADH (25 mg/ml)
with a mixture of dextran-CHO50 (60 mg) and dextran-CHOn-AmB62.5 (48 mg) per ml of PBS,
by injection from a double barrel syringe. This mixture with dextran-CHO50 unconjugated to
AmB was used to compensate for the relatively low number of aldehyde sites available for
cross-linking in the AmB-conjugated dextrans (Table 1). (In other words, dextran-CHOn-
AmBm was party entrapped in the hydrogel via covalent linkage to CMC-ADH, and partly by
entrapment within the CMC-dextran hydrogel.) Gels of poor consistency were formed when
CMC-ADH and dextran-CHO66-AmB62.5 were used without additional dextran-CHO50.
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Upon release from the gel matrix after 6 days, the UV-visible spectrum of the release media
was very similar to that of freshly dissolved dextran-CHOn-AmBm, (compare Fig. S1 and Fig.
5a). This implies that it is dextran-CHOn-AmBm and not free AmB that is released from the
gels. The total amount of dextran-CHOn-AmB62.5 released over time was slightly higher with
increasing degree of oxidation of the dextran (Fig. 5b). Lower degrees of oxidation may have
resulted in less of the dextran-CHOn-AmB62.5 being conjugated to CMC-ADH.
Gels containing the AmB suspension were formed by combining CMC-ADH (25 mg/ml) with
a mixture of dextran-CHO50 (60 mg) and AmB (3 mg) per ml of PBS, by injection from a
double barrel syringe. The release medium was changed and tested each day. UV-visible
spectral analysis of the release media showed that very little AmB was released (data not
shown).
Antifungal activity of AmB in CMC-dextran gels
Gel discs were produced by cross-linking CMC-ADH with dextran-CHO50 containing a
suspension of AmB or dextran-CHOn-AmBm as described above. The former was yellow and
cloudy while the latter was translucent even though very yellow. Gel discs were placed on agar
plates that had been inoculated with C. albicans and incubated at 37 °C in darkness. After 1
day, discs containing dextran-CHO33-AmB62.5 and dextran-CHO66-AmB62.5 were surrounded
by a clear halo, a zone free of fungal growth, which remained for four days until the plates
were disposed of. There was no such halo around gels made with a suspension of AmB (Fig.
6).
Separate gel discs were incubated in YNB media at 37 °C in darkness. At predetermined
intervals, the media (with released fungicide; Fig. 7) were tested for antifungal activity. The
release media were added to YNB media containing 107 colonies of C. albicans. Release media
from gels containing a suspension of AmB exhibited very little fungal killing after day 1 while
the release media from the gels containing dextran-CHO33-AmB62.5 killed for 3–4 days and
those containing dextran-CHO66-AmB62.5 killed for as long as 11 days. The antifungal agent
(dextran-CHOn-AmBm) is released as the CMC-dextran gels slowly swell and the hydrazone
bond between the antifungal agent and the CMC-ADH is hydrolysed. The release media from
blank gels had no antifungal activity.
Similarly, gel discs incubated at 37 °C in darkness were placed in YNB media containing
107 colonies of C. albicans at predetermined intervals (Fig. 8). Gels containing dextran-
CHO33-AmB62.5 stopped killing after 6 or 7 days, while those containing the more highly
oxidized dextran-CHO66-AmB62.5 retained antifungal activity for longer than 3 weeks.
Interestingly, discs containing a suspension of AmB exhibited strong antifungal activity for 3
weeks (Fig. 8), even though their release media had only shown antifungal activity for 1 day.
Blank gels did not exhibit any antifungal activity and became infected with Candida after the
first incubation period.
Intraperitoneal biocompatibility
Cross-linked CMC-dextran gels, made with dextran-CHO66-AmB62.5, with dextran-CHO33-
AmB62.5 and blank gels were injected into the peritoneum with a double-barrelled syringe (see
Methods section for details of groups and sample sizes). We selected the peritoneum for the
assessment of biocompatibility as it is relatively prone to adverse tissue reactions [12]
compared to subcutaneous tissue [18]. Furthermore, it resembles some of the spaces in which
such formulations might be used clinically (peritoneum, pleura, synovium). We have
previously shown that tissue reaction to CMC-dextran gels is benign, and in fact the gel
prevents adhesions in the injured peritoneum [19]. However, the gels used here contained a
high concentration of a hydrophobic drug, which could alter the biocompatibility.
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Injected animals did not demonstrate abnormalities in feeding, grooming, or behavior during
the time frame of the experiment nor did they exhibit signs of distress. On dissection 1 week,
11 days and 33 days after injection, all gels appeared to have crosslinked rapidly but not
immediately, as the gel had spread throughout the peritoneum, coating the viscera (Fig. 9). The
gels had a soft consistency, but also formed discrete collections. The gels were difficult to
recover completely, but gross observation suggested that a significant fraction of gel mass was
retained on day 33. No adhesions were observed at any time point in any group. Light
microscopy of hematoxylin-eosin stained sections showed an absence of injury to
mesothelium, smooth muscle or any other cell type (Fig. 10). The gels themselves showed
relatively little inflammation; the inflammation in Fig. 10(a) is on the high end of what was
seen. Inflammatory cells were largely macrophages with occasional neutrophils and plasma
cells. Lymphocytes were seen at later time points, as were giant foreign body cells around small
collections of gel. The looseness of the association between the gel and the tissues was reflected
in the fact that very few slides showed gel remaining in contact with tissue.
Discussion
We produced and characterized a variety of novel fungicidal formulations incorporating AmB.
Our principal aim was the development of in situ cross-linking gels for the extended therapy
of localized infections, especially of anatomic spaces such as the synovia. The formulations
we created, cross-linked gels containing AmB conjugated to the hydrogel or suspended in the
matrix, were both effective in killing fungi on contact, suggesting that they both could be useful
in preventing infections, in a manner analoguous to our observations in a different non-
injectable hydrogel-based system containing AmB [4]. The somewhat unusual property of
contact killing of fungi in the absence of detectable release of antifungal activity was also noted
in that report. However, one would anticipate that the gel with conjugated AmB would be more
likely to be useful in the context of established infections, because it would release antifungal
activity, which would then be able to penetrate infected tissues. These in situ cross-linking gels
are appealing in that they easy to apply, would conform to the shape of the space in which they
are injected, and would provide sustained antifungal therapy. As we show here, they would
remain in situ at the site of injection for the duration of therapy. Furthermore, their
biocompatibility in the peritoneum was excellent, and their consistency is such that they would
not be likely to be deleterious in weight-bearing joints, etc.
Current therapy of invasive candidiasis – and of other fungal infections – requires prolonged
administration of antifungal agents [20]. Treatment generally commences with an intravenous
course of two weeks or more, followed by protracted therapy with an oral agent (e.g. up to a
year for candidal osteomyelitis). During the period of intravenous therapy, patients are exposed
to the difficulties and risks of maintaining intravascular access over weeks; then and
subsequently, they are at risk for the systemic side effects of the antifungal agents used (e.g.
nephrotoxicity for AmB). Formulations like ours – with AmB and/or other compounds - would
be able to provide local therapy at the site of infection from a single injection for durations that
are comparable to those that are currently recommended, and at concentrations that would be
difficult or impossible to achieve safely via systemic therapy. Local therapy could be
particularly advantagous in pregnancy, where there may be concerns over birth defects with
some antifungal agents [21]. We note that current recommendations for many local infections
(e.g. endophthalmitis, osteomyleitis, pericarditis) suggest some form of surgical intervention
for diagnostic or therapeutic (debridement) purposes, making it possible to deliver such local
treatments to those locations safely. It remains to be seen whether such treatments would result
in improved cure rates, and/or mitigate or obviate the need for concurrent systemic therapy.
We also note that formulations of this type could in theory act as depots to provide systemic
therapy in patient or communities where sustained intravenous access is either impractical or
impossible.
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There are numerous existant sustained release systems, including hydrogels and particulates.
Some have been used to deliver antifungal agents topically or systemically, and it is possible
that such could be adapted for use in local infections. The specific advantages of our system
include prolonged duration of therapy, high local drug concentrations, ease of application,
ability of the material to conform to the shape of the surface to which applied, tunability of a
number of physical parameters, and biocompatibility.
AmB conjugated to oxidized dextran was effective against C. albicans. The fact that it was
water soluble makes it potentially useful for intravasacular injection. AmB has been conjugated
to other hydrophilic polymers and natural polysaccharides including arabinogalactan [14],
dextran [15,22], gum arabic [16] and PEG [23]. These conjugates have been shown to reduce
the toxicity of AmB in mice [14,16,22,23].
The polysaccharides used here were selected because of their biocompatility and their slow
degradation due to the relatively low concentration (dextranases) or absence (cellulases) of
human enzymes that degrade them. Some degradation would, however, be expected to occur
by hydrolytic cleavage of the hydrazone bond, and eventually perhaps through the action of
inflammatory cells. Other polysaccharides, such as hyaluronic acid, would allow more rapid
degradation [12]. The tissue dwell time of the hydrogel matrix could be tuned to match the
release kinetics of whatever drug is delivered – this could be desirable if repeated injection
was anticipated.
Conclusions
We have produced injectable in situ cross-linking gels with extended antifungal activity.
Depending on the formulation, they have the potential to kill fungi by drug release and/or on
contact. There was no evidence of tissue injury after intraperitoneal injection, or of hemolysis
from these hydrogels. Cross-linked hydrogels containing AmB have the potential to provide
sustained local antifungal therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
UV-visible absorption spectra of dextran-CHO33-AmB62.5, dextran-CHO33-AmB12.5
(normalised), AmB suspension (after centrifugation) in PBS and AmB in methanol.
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Figure 2.
Antifungal activity of AmB in suspension, dextran-CHO33-AmB62.5 and dextran-CHO33-
AmB12.5. The lower detectable limit of candidal survival was 0.2 %. (The x-axis shows the
concentration of AmB present on polymer conjugate or in suspension)
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Figure 3.
Antifungal activity over time of 0.1 mg/ml AmB and 1.6 mg/ml dextran-CHO33-AmB62.5. The
lower detectable limit of candidal survival was 0.2 %.
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Figure 4.
(a) Photograph of cross-linked CMC-dextran hydrogel, (6 mm scale bar shown). (b) SEM of
same, lyophilised, (20μm scale bar shown).
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Figure 5.
(a) UV-visible absorption spectra of dextran-CHO75-AmB62.5, dextran-CHO66-AmB62.5 and
dextran-CHO33-AmB62.5 released after 144 hours from CMC-Dextran gel. (b) Release kinetics
of dextran-CHOn-AmB62.5 from CMC-Dex gel discs into PBS at 37°C; data are means with
standad devations (n = 4).
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Figure 6.
Petri plate assay for killing of Candida albicans. Each of the plates has a confluent lawn of
cells except where the drug diffused out of the central gel disc and killed them leaving a clear
zone. The gel discs consisted of CMC-dextran gels containing (a) dextran-CHO33-AmB62.5
(24 mg/ml), (b) dextran-CHO66-AmB62.5 (24 mg/ml) and (c) a suspension of AmB (1.5 mg/
ml).
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Figure 7.
Antifungal activity of the release media from CMC-Dex gels containing AmB suspension,
dextran-CHO33-AmB62.5 and dextran-CHO66-AmB62.5, each formulation containing 1.5 mg
AmB/mL upon gelation of CMC-Dextran gels. The release media (YNB) was changed and
tested each day and stored shaking in darkness at 150 rpm at 37°C between tests. The lower
detectable limit of candidal survival was 0.2 %.
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Figure 8.
Anti-fungal activity of CMC-dextran gels containing AmB suspension, dextran-CHO33-
AmB62.5 and dextran-CHO66-AmB62.5, each formulation containing 1.5 mg AmB/mL upon
gelation of CMC-Dextran gels. The release media (YNB) was changed and tested each day
and stored shaking in darkness at 150 rpm at 37°C between tests. The lower detectable limit
of candidal survival was 0.2 %.
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Figure 9.
CMC-Dex gels 11 days after intraperitoneal injection. (a) blank, (b) dextran-CHO66-
AmB62.5 and (c) dextran-CHO33-AmB62.5. Arrows indicate remaining gel mass.
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Figure 10.
Photomicrographs of hematoxylin-eosin stained sections of injected CMC- dextran-CHO66-
AmB62.5 11 days after injection A. Inflammatory reaction to a collection of hydrogel in the
peritoneal cavity (magnification 200X); most inflammation seen was less than this. B. Intact
peritoneal mesothelium (the thin layer of cells overlying the abdominal wall musculature). C.
Interface between gel and the outside of the bowel. H: hydrogel, I: inflammation, M: abdominal
wall muscle, B: bowel, arrows: nuclei of mesothelial cells.
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Scheme 1.
Conjugation of AmB to oxidized dextran and the incorporation of the dextran-CHO-AmB into
a CMC-Dextran gel.
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Table 1
Characterisation of polymer components by weight average and number average molecular weights (Mw and
Mn), the degree of functionalisation by hydrazine (CMC) and the degree of oxidation of the dextrans before and
after conjugation with amphotericin B.
Polymer Mwa (kDa) Mna (kDa) NaIO4 (mol %)c
Measured degree of
functionalisation
CMC 250b - - -
CMC-ADH 810.3 77.7 - 51 %
Dextran 100–200b - - -
Dextran-CHO33 27.6 6.8 45 35 %d
Dextran-CHO50 21.4 5.7 64 48 %d
Dextran-CHO66 19.4 5.0 90 66 %d
Dextran-CHO75 18.0 5.0 96 75 %d
Dextran-CHO33-AmB12.5 8.0e 3.1e - 15 %d
Dextran-CHO33-AmB62.5 8.1e 3.1e - 5 %d
Dextran-CHO66-AmB62.5 7.9e 2.6e - 13 %d
Dextran-CHO75-AmB62.5 8.3e 2.5e - 18 %d
a
Relative to Pullulan standards,
b
According to provider,
c
Mol% defined as [IO4-]/[glucose] × 100
d
Number of aldehyde groups per 100 glucose units,
e
Contained multiple components.
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